OIG Sides With Manufacturers On Calculating Sales To Retail Pharmacies For Final AMP Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
In a report on manufacturers’ average manufacturer price practices, the HHS Office of Inspector General says the industry’s current use of “presumptive inclusion” to determine when drug sales are made through a retail community pharmacy should be retained, contrary to what CMS proposed in its draft AMP rule.
You may also be interested in...
Medicaid AMP: Manufacturers Have Reason To Hope For Significant Changes In Final Rule
A major regulation that could reshape how the pharmaceutical industry reports drug pricing to the government and pays rebates on Medicaid drugs is slated to be released in final form in 2014. Some Medicaid regulatory experts suggest that CMS could make changes in the final rule that will make it less disruptive to manufacturers’ businesses than they have feared.
Medicaid Rx Stakeholders Appeal To CMS Chief For Help In Reversing AMP Proposal
PhRMA, BIO, GPhA, HDMA and NACDS send joint letter to CMS Acting Administrator Marilyn Tavenner asking that the agency not finalize its proposal to require drug manufacturers to base average manufacturer price calculations only on actual sales to retail community pharmacies – barring use of the customary “presumed inclusion” method.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.